ScreenerHero

AKTSAktis Oncology, Inc.

NAS · US · Technology · Biotechnology · aktisoncology.com
24.07USD-3.80%Mkt Cap: 1.34B $P/E: —

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.34B $
Enterprise Value828.79M $
Revenue (TTM)10.06M $
Gross Profit-68.22M $
Net Income (TTM)-63.73M $
Revenue/Share0.3810 USD
Last Price24.07 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees79
CountryUS
SectorTechnology
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.56
PEG—
EV/EBITDA-9.82
EV/Revenue82.38
P/S132.69
P/B2.74
EPS (TTM)-1.27
EPS (Forward)-2.08
52W Range
14.7248% of range34.19
52W High34.19 USD
52W Low14.72 USD
Profitability
Gross Margin0.00%
Oper. Margin-853.99%
EBITDA Margin0.00%
Profit Margin-980.93%
ROE43.61%
ROA-24.06%
Growth
Revenue Growth111.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-64.13M $
CapEx (TTM)9.58M $
FCF Margin—
FCF Yield—
Net Debt-506.08M $
Net Debt/EBITDA6.00
Balance Sheet
Debt/Equity-0.08
Current Ratio16.33
Quick Ratio16.17
Book Value/Sh8.764 USD
Cash/Share9.301 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)34.81 USD
Upside (mean)+44.6%
Target Range31.50 USD – 40.00 USD
$31.50+44.6% to mean$40.00
# Analysts8
Ownership
Shares Out.53.75M
Float28.59M
Insiders14.05%
Institutions72.89%
Short Interest
Short Ratio7.6d
Short % Float21.93%
Short % Out.6.28%
Shares Short3.47M
Short (prev mo.)3.31M
Technical
SMA 5025.09 (-4.1%)
SMA 20021.17 (+13.7%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)296.08K
Avg Vol (10d)202.12K
Technical Indicators
RSI (14)48.6
MACD-0.0171
MACD Signal-0.1370
MACD Hist.+0.1200
BB Upper25.64 USD
BB Middle23.72 USD
BB Lower21.80 USD
BB Width16.20%
ATR (14)1.443 USD
Vol Ratio (20d)0.92x